News
SLDB
6.84
-2.29%
-0.16
Solid Biosciences (SLDB) Gets a Buy from J.P. Morgan
TipRanks · 2d ago
Circio Enters Research Collaboration With Solid Biosciences To Evaluate Combining CircVec Generation 5 Construct With POLARIS-101 AAV Capsid For Genetic Heart Disease Gene Therapy
Benzinga · 3d ago
William Blair Assumes Solid Biosciences at Outperform
Benzinga · 5d ago
Solid Biosciences a new Outperform at William Blair on Duchenne asset
Seeking Alpha · 5d ago
Solid Biosciences assumed with an Outperform at William Blair
TipRanks · 5d ago
Weekly Report: what happened at SLDB last week (1102-1106)?
Weekly Report · 5d ago
Solid Biosciences (SLDB) Gets a Buy from RBC Capital
TipRanks · 11/05 14:36
Leerink Partners Sticks to Their Buy Rating for Solid Biosciences (SLDB)
TipRanks · 11/05 14:29
Solid Biosciences (SLDB) Gets a Buy from Piper Sandler
TipRanks · 11/05 12:29
Analysts Offer Insights on Healthcare Companies: Bruker (BRKR), Zevra Therapeutics (ZVRA) and Solid Biosciences (SLDB)
TipRanks · 11/05 12:20
H.C. Wainwright Sticks to Their Buy Rating for Solid Biosciences (SLDB)
TipRanks · 11/05 12:16
Press Release: Solid Biosciences Reports Third -2-
Dow Jones · 11/04 21:07
Weekly Report: what happened at SLDB last week (1026-1030)?
Weekly Report · 11/02 09:06
Solid Biosciences Set to Report Whether Gene Therapy Losses Are Narrowing on Schedule
Barchart · 10/30 16:11
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Simply Wall St · 10/30 10:33
Solid Biosciences Receives EU Orphan Drug Designation For SGT-212 In Friedreich's Ataxia
NASDAQ · 10/26 17:13
Solid Biosciences granted Orphan designation for SGT-212
TipRanks · 10/26 12:38
Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia
Benzinga · 10/26 12:03
Weekly Report: what happened at SLDB last week (1019-1023)?
Weekly Report · 10/26 09:06
Leerink Partners Remains a Buy on Solid Biosciences (SLDB)
TipRanks · 10/20 11:58
More
Webull provides a variety of real-time SLDB stock news. You can receive the latest news about Solid Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.